Adverum to Present Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2021 Virtual Meeting
Adverum Biotechnologies (Nasdaq: ADVM) announced data from Cohorts 1-4 of the OPTIC Phase 1 clinical trial for ADVM-022, a gene therapy targeting wet age-related macular degeneration (AMD).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adverum Biotechnologies (Nasdaq: ADVM) announced data from Cohorts 1-4 of the OPTIC Phase 1 clinical trial for ADVM-022, a gene therapy targeting wet age-related macular degeneration (AMD). The presentation will take place on February 13, 2021, at 9:30 am ET, showcasing the therapy's potential benefits for patients requiring frequent anti-VEGF treatments. ADVM-022 represents a significant advancement in treating AMD and diabetic macular edema, aiming for a one-time intravitreal injection solution.
Positive
- Presentation of Phase 1 trial data for ADVM-022 targeting AMD, indicating potential effectiveness.
- Focusing on unmet medical needs in ocular conditions with a novel gene therapy approach.
- Scheduled oral presentation suggests ongoing engagement in clinical research.
Negative
- None.
Details
News Market Reaction – ADVM
The recorded move for ADVM in the trading session of this news was +0.80%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of data from Cohorts 1-4 of the OPTIC Phase 1 clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). These data were previously presented as part of a corporate update on Saturday, November 14, 2020.
Oral Presentation Title: Intravitreal Gene Therapy for Exudative AMD and Diabetic Retinopathy
Date and Time: Saturday, February 13, 2021 at 9:30 am ET
Session V: Gene Therapy for Exudative AMD and Diabetic Retinopathy
Presenter: Arshad M. Khanani, M.D., M.A., Director of Clinical Research, Sierra Eye Associates
A copy of this presentation will be available as the presentation begins in the publications and presentation section of Adverum’s website.
About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.